Paclitaxel and ramucirumab switch maintenance could be a potential treatment strategy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer who are not eligible for immunotherapy or targeted agents.
Alan Percy, MD, discusses long-term data from clinical trial extension of trofinetide in patients with Rett syndrome.
To celebrate Native American Heritage Month, we spoke with Karina Walters, Ph.D., M.S.W., Director of the NIH Tribal Research Health Office (THRO). Dr. Walters, an…
Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.
Although HbA1c testing remains the gold standard for glucose monitoring in type 1 and type 2 diabetes, limitations include its inability to provide data around…
These CGM data support the long-term efficacy and safety of icodec versus glargine U100 during treatment and indicated no increase in the duration of individual…
In this studio-based webinar, a multidisciplinary expert panel will address the new treatment landscape of metastatic UCa via interactive case discussions on managing AEs and…
Earlier this year, Jarno Habicht, the WHO Representative in Ukraine, described the situation there as a “humanitarian crisis of unprecedented scale”. He noted that a…
Oxford University Press (OUP) invites applications for the position of Deputy Editor for The Oncologist. There are two Deputy Editor positions available, each
The diagnostic abilities for assessing prostate cancer patients have significantly evolved in the last years. Ranging from advanced imaging modalities for detection, new innovative liquid…
The phase 2 ASCENT trial assessed the efficacy and safety of afatinib and concurrent chemoradiotherapy with or without surgery in locally advanced epiderma
